MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2478/rjim-2026-0005

Медицинская библиотека · Romanian journal of internal medicine = Revue roumaine de medecine interne · 2026

Blood Pressure Alterations in CML Patients Treated with Imatinib vs. Nilotinib: A Clinical Insight.

Anwar Wardiyanti, Harjianti Tutik, Tandean Pendrik, Bakri Syakib, Hp Faridin, Zainuddin Andi Alfian

СтатьяСравнительное исследованиеПеревод в очереди

Аннотация

INTRODUCTION

Chronic Myeloid Leukemia is a hematologic malignancy characterized by the BCR-ABL fusion gene. Tyrosine Kinase Inhibitors such as imatinib and nilotinib have significantly improved the prognosis for CML patients. However, prolonged TKI therapy is associated with cardiovascular side effects, particularly hypertension. This study aims to compare the effects of imatinib and nilotinib on blood pressure in CML patients over a 12-month period.

METHODS

A retrospective cohort study was conducted at Wahidin Sudirohusodo Hospital, including 148 adult CML patients who received imatinib or nilotinib for at least 12 months. BP measurements were taken at baseline, and at 3, 6, 9, and 12 months. Statistical analyses included paired t-tests and multivariate regression to evaluate BP changes and their associations with demographic and treatment variables.

RESULTS

Both systolic and diastolic BP significantly increased in both groups over 12 months. In the imatinib group, systolic BP rose from 112 mmHg to 125 mmHg, and diastolic BP increased from 72 mmHg to 81 mmHg. In the nilotinib group, systolic BP increased from 111 mmHg to 130 mmHg, and diastolic BP rose from 70 mmHg to 83 mmHg. These increases were more pronounced in the nilotinib group (p < 0.001 for systolic and p = 0.006 for diastolic).

CONCLUSION

Both imatinib and nilotinib therapies lead to significant increases in BP, with nilotinib showing a greater hypertensive effect. Monitoring BP is crucial, especially for patients on second-generation TKIs, to manage cardiovascular risks associated with long-term treatment.

Для цитирования: Anwar Wardiyanti, Harjianti Tutik, Tandean Pendrik, Bakri Syakib, Hp Faridin, Zainuddin Andi Alfian. Blood Pressure Alterations in CML Patients Treated with Imatinib vs. Nilotinib: A Clinical Insight.. Romanian journal of internal medicine = Revue roumaine de medecine interne. 2026. DOI: 10.2478/rjim-2026-0005.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.